CellMax Life Announces Expansion of GI Medical Advisory Board

Share Article

Renowned industry experts support the company as it prepares for premarket approval studies

CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the expansion of its medical advisory board. The board is comprised of highly respected and experienced leaders in colorectal cancer screening and prevention.

The company welcomed four new members to its existing board, which consisted previously of Shai Friedland, MD, a gastroenterologist at Stanford Medicine, Ashish Nimgaonkar, MD, a gastroenterologist at Johns Hopkins Medicine, and Samir Gupta, MD, a gastroenterologist at UC San Diego Health, who will all continue to serve on the board.

The new board members include: Douglas Rex, MD, a gastroenterologist at Indiana University Health; Aasma Shaukat, MD, a gastroenterologist at NYU Langone Health; Brooks Cash, MD, a gastroenterologist at UTHealth Houston; and Jack Di Palma, MD, a gastroenterologist at USA Health.

"It is my honor to welcome these industry leaders who bring significant depth of expertise in the field of colorectal cancer, especially as it relates to prevention and screening; they will bring significant value as we build and launch our premarket approval study,” said Atul Sharan, CEO of CellMax Life. “With their guidance we are confident that FirstSight will play a crucial role in increasing screening adherence and reduce mortality with its ability to detect precancerous adenomas.”

Each new board member brings an impressive background.

  • Douglas Rex, MD, is a distinguished professor emeritus of medicine at Indiana University School of Medicine. Previously, he served on the U.S. Multi-Society (ACG, ASGE, AGA) Task Force on Colorectal Cancer and as president of the American Society for Gastrointestinal Endoscopy (ASGE). Dr. Rex co-authored the colorectal cancer screening recommendations of the American College of Gastroenterology and the U.S. Multi-Society Task Force on Colorectal Cancer. He has authored more than 330 original research papers, 60 book chapters, 60 editorials, and 40 guideline papers.
  • Aasma Shaukat, MD, is a professor of medicine with the Department of Medicine at NYU Grossman School of Medicine and a professor with the Department of Population Health at NYU Grossman School of Medicine. She is the first author of the newly updated "ACG Clinical Guidelines: Colorectal Cancer Screening 2021” and is highly regarded as a thought leader in the space, publishing over 160 peer-reviewed articles in numerous top-tier medical publications
  • Brooks Cash, MD, is chief of the division of gastroenterology, hepatology, and nutrition at the University of Texas Health Science Center at Houston. He also serves as a professor of medicine at the University of Texas McGovern Medical School and is a Senior Associate Editor for the American Journal of Gastroenterology. A recognized expert in evidence-based clinical care, Dr. Cash has conducted pioneering research in emerging testing options for colorectal cancer screening, has authored more than 250 original research papers, review articles, and guidelines in prestigious medical journals, and has served as editor and contributor to 15 gastroenterology focused textbooks.
  • Jack Di Palma, MD, is program director of the division of gastroenterology at University of South Alabama Health and the director of section of inflammatory bowel diseases at University of South Alabama Health. Dr. Di Palma also works as a professor of internal medicine and digestive health at University of South Alabama Health and previously served as President of the American College of Gastroenterology (ACG).

“I am excited to join CellMax’s medical advisory board and to be with this highly accomplished group that brings significant experience in gastroenterology, and in particular, colorectal cancer screening and prevention,” said Dr. Rex. “In order to significantly reduce mortality associated with colorectal cancer, a blood-test that can detect both CRC & AAs with high sensitivity is needed. This is why I am enthusiastic about FirstSight.”

About CellMax Life:

CellMax Life is a diagnostics company focused on cancer screening with proprietary technology for detecting precancerous and cancer cells and genomic aberrations in a single blood sample. CellMax Life is headquartered in Sunnyvale, California, and has an accredited laboratory at this location. For more information, visit http://www.cellmaxlife.com.


As Principal Investigator for CellMax clinical studies Dr. Shai Friedland's position as a medical advisory board member is not compensated.

Media Contact:

Leonard Fontes III

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Leonard Fontes III
CellMax Life
1 (551)-287-2970
Email >